ArticleInternational journal of energy research2021
Application of microfluidic paper-based analytical device (μPAD) to detect COVID-19 in energy deprived countries.
Article in International journal of energy research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Affordable Arsenic Detection Device Using Handmade Lokta Paper for Decentralized and Sustainable Manufacturing.Journal of analytical methods in chemistry · 2026Article
- Latest Advances in Arbovirus Diagnostics.Microorganisms · 2023Review
- Paper-based analytical devices for point-of-need applications.Mikrochimica acta · 2023Review
- Porous Cellulose Substrate Study to Improve the Performance of Diffusion-Based Ionic Strength Sensors.Membranes · 2022Article
- Microfluidics-based strategies for molecular diagnostics of infectious diseases.Military Medical Research · 2022Review
- Application of microfluidic paper-based analytical device (μPAD) to detect COVID-19 in energy deprived countries.International journal of energy research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coronavirus disease (COVID-19) has spread all across the world. Low- and medium-income countries are more affected economically and socially compared to developed countries due to the lack of a rapid, robust, and affordable testing infrastructure. Furthermore, the high cost of real-time polymerase chain reaction (PCR) system, sophisticated user-handling procedure, and high expense of the conventional clinical tests are the root causes of the less accessibility of the testing systems to the users. In this study, a COVID-19 Point-of-Care (POC) ecosystem model is proposed for the low- and medium-income countries (or energy deprived countries) that will facilitate the technological development with locally available fabrication components. In addition, the nontechnological development phases have also been discussed, which encompasses the collaboration among academia, local as well as government bodies, and entrepreneurial ventures. In addition, a hypothetical design of a microfluidic paper-based analytical (μPADs) POC platform is proposed to detect COVID-19 analyte using unprocessed patient-derived saliva, which is a miniaturized form-factor of conventional real-time polymerase chain reaction (PCR) technique. The device contains four major reaction zones, which are sample zone, buffer zone, loop-mediated isothermal amplification (LAMP) Master Mix zone, Ethylenediamine tetraacetic acid (EDTA) zone, and sensor zone. To obtain quicker test results and easier operation, a handheld image acquisition technique is introduced in this study. It is hypothesized that in a remote setting, the proposed design could be used as an initial guideline to develop a POC COVID-19 testing system, which may be simple, easy-to-use, and cost-effective.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.